Loading...
Bhang Inc.
BHNG.CN•CNQ
Healthcare
Drug Manufacturers - Specialty & Generic
CA$0.02
CA$0.00(0.00%)

Financial performance has remained strong, with revenue growing from $384670.00 in Q4 2021 to $363103.00 in Q3 2022. Gross profit continued to perform well, with margins at 75% in the latest quarter. Operating income reached -$773709.00 in Q3 2022, holding a steady -213% margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at -$1.005M. Net income rose to -$981738.00, keeping EPS at -$0.004. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan